MAPT and Alzheimer disease: Major reasons for this include the relatively stable trajectory of CSF (amyloid and tau) or PET amyloid biomarkers once in the symptomatic stages of AD3–6, clinical and pathologic AD heterogeneity, and mixed pathologies.